Summit Therapeutics partners with Lunit to study AI tumor biomarkers for ivonescimab
Summit Therapeutics and Lunit will study AI-derived tumor biomarkers for ivonescimab, while clinical validation and patient-selection benefits remain unproven.
Pharma & Biotech
Pharma & Biotech
Travere Therapeutics FILSPARI shows sustained biomarker reductions in Phase 3 PROTECT study
Travere's FILSPARI reduced four IgA nephropathy biomarkers in new PROTECT data, adding evidence on kidney protection without proving disease modification.
Pharma & Biotech
Genialis AI predicts cancer treatment response in small clinical trials using biology-first models
Genialis reports improved cancer response prediction using small patient cohorts and longitudinal AI analysis. Clinical validation remains the next hurdle.
Pharma & Biotech
AdvanCell reports 80% PSA response with ADVC001 in updated Phase 1 prostate cancer study
AdvanCell reports an 80% PSA response and 11.2-month median rPFS with ADVC001. Small Phase 1 numbers leave important efficacy questions.
Pharma & Biotech
Galderma wins China approval for Relfydess, but can its six-month wrinkle treatment challenge established Botox rivals?
Galderma wins China approval for Relfydess after positive Phase 3 frown line results. Competition and its pending US review remain crucial.
Medical Devices & Diagnostics
EQT offers QIAGEN shareholders a 40% premium, but can its €10.8bn diagnostics bet unlock faster growth?
EQT agrees a €10.8 billion takeover of QIAGEN at €46.50 per share. Diagnostics growth, financing and shareholder approval remain key.
Pharma & Biotech
Merck and Moderna report 42% lower melanoma recurrence risk in Phase 3 mRNA trial
Merck and Moderna report 42% lower melanoma recurrence risk with intismeran plus Keytruda. Survival, safety and manufacturing remain key.
Pharma & Biotech
Drug Farm reports DF-003 reduces kidney fibrosis in preclinical ALPK1 study
Drug Farm reports DF-003 reduced kidney fibrosis in preclinical research, revealing a potential ALPK1 treatment pathway. Human efficacy remains unproven.
Pharma & Biotech
Gilead Sciences makes a $1.275bn bet on an early-stage oral drug. Can HCXT-2001 challenge injectable IBD therapies?
Gilead Sciences agrees a $1.275 billion deal for HCXT-2001, an oral IL-23R inhibitor. Its IBD potential faces major clinical tests.
Pharma & Biotech
Innate Pharma faces a crucial November update. Can its ADC pipeline and Sobi deal strengthen its position?
Innate Pharma plans its November 5 update as IPH4502 data, the Sobi partnership and monalizumab milestones approach. Key clinical questions remain.